Red Cell Life Span (RBC) in Chronic Kidney Disease (CKD)

Red Blood Cell (RBC) Survival in Patients with Chronic Kidney Disease (CKD) and on Dialysis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12610000145000

Enrollment

Registered

2010-02-12

Start date

2009-10-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Anaemia associated with chronic kidney disease (CKD) is believed to be caused by erythropoietin deficiency and decreased red blood cell (RBC) survival. The toxic uremic environment and mechanical damage caused by dialysis is thought to account for the reduced red cell life span. However the clinical evidence for this is minimal. To date no accurate data on RBC survival in CKD is available. We propose to undertake a study to investigate red blood cell survival in patients with moderate CKD, on haemodialysis and on peritoneal dialysis in comparison with controls. RBC survival will be measured by means of labelling with radioactive chromium. As almost half the patients with CKD are diabetic, glycaemic control remains an important aspect of their management. Therefore RBC survival will influence the accuracy of markers of glycaemic control, like HbA1c.

Interventions

This study is designed to investigate red blood cell survival in patients with moderate CKD, on haemodialysis and on peritoneal dialysis in comparison with controls. RBC survival will be measured by means of labelling with radioactive chromium, whereby a sample of RBCs of a cross-section of ages is tagged and the disappearance of radioactivity is followed over a period of 4 weeks time.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Patients of at least 18 years of age and on dialysis at least for 2 months haemodialysis (HD) and peritoneal dialysis (PD) will be invited to participate in this study, stable subjects with moderate CKD (stage III, defined as a glomerular filtration rate (GFR) (30-59 ml/min), subjects with diabetes mellitus with normal renal function and healthy controls

Exclusion criteria

HD and PD patients not on erythropoietin and/or iron supplement therapy. Haemoglobin concentrations not within the recommended target range (Hb: 110-130 g/l). Evidence of recent blood loss and or recent blood transfusion. Intercurrent inflammatory illness or drugs which may influence bone marrow function. Solid organ maligancy. Unstable glycaemic control. Pregnancy. Women of child bearing potential will be advised to practise ab acceptable form of contraception for the duration of the study.

Outcome results